-- Completed a Phase I multiple dose clinical trial of tezampanel that
demonstrated the compound to be safe and well-tolerated, supporting the
development of tezampanel in pain and non-pain indications that require
-- Completed dosing of up to 210 mg of NGX426 in a Phase I maximum
tolerated dose trial evaluating the oral prodrug of tezampanel.
Following completion of this trial TorreyPines intends to initiate a
multiple dose clinical trial of NGX426 to support the chronic dosing of
-- Pharmacokinetic data from the ongoing Phase I maximum tolerated dose
trial of NGX426 suggest that 90 mg of NGX426 results in blood levels of
tezampanel that the company believes will prove to be analgesic.
TorreyPines intends to initiate a study in a model of capsaicin-induced
pain to confirm the analgesic activity of NGX426 administered orally,
with data from this study expected by the end of year.
-- Initiated a Phase II study of NGX267 for the treatment of xerostomia,
or dry mouth, secondary to Sjogren's syndrome. Data from this study
are expected by the end of year.
-- Presented animal data on TorreyPines' proprietary gamma secretase
modulator (GSM) compounds at the Keystone Symposium on Alzheimer's
disease. The data demonstrated that TorreyPines' GSM compounds provide
a more selective mechanism than gamma secretase inhibitors.
TorreyPines is developing its GSM compounds as a potential treatment
for Alzheimer's disease.
-- Acquired from Johns Hopkins University the rights to intellectual
property related to the novel use of glutamate receptor antagonists,
including TorreyPines' compounds tezampanel and NGX426, for the
prevention and treatment of stroke
|SOURCE TorreyPines Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved